Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TREST is an oral small-molecule tablet in pre-launch development by Novartis for cardiovascular and respiratory indications including heart failure, hypertension, acute myocardial infarction, congenital heart disease, and COVID-19. The mechanism of action and generic name remain undisclosed, limiting assessment of its differentiation in a crowded cardiology market.
Pre-Launch
Pre-launch stage signals early-phase commercial planning with potential for significant team expansion once regulatory clarity emerges; currently limited hiring activity.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (10)
Entresto Tablets and Granules for Pediatric Specified Drug-use Survey (Pediatric Chronic Heart Failure)
Started Dec 2024
30 enrolled
Pediatric Chronic Heart Failure
Sacubitril 97 mg and Valsartan 103 mg Film-coated Tablets Relative to Entresto 97 mg/103 mg Film-coated Tablets
Started May 2024
40 enrolled
Healthy Subjects
Special Drug Use Surveillance of Entresto Tablets (Hypertension)
Started Sep 2023
1,125 enrolled
Hypertension
Real World, Pharmacy-assessed Adherence to New Onset Entresto® (Sacubitril/Valsartan) in Patients With Chronic Heart Failure
Started May 2023
0Heart Failure
Effectiveness of Entresto (Sacubitril/Valsartan) in Japanese Patients With Hypertension
Started Jan 2023
1,405 enrolled
Essential Hypertension
Worked on TREST at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.